TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38858629
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TaU)
Study: 34764014
Drug: Acupressure at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure at the BL67 point for 10 minutes daily for two consecutive weeks
Study: 35510486
Drug: Imetelstat 9.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat 9.4 mg/kg administered as an intravenous infusion every 21 days
Study: 35510486
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy, excluding JAK inhibitors
Study: 33243811
Drug: Individualised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised physical exercise training programmes combined with increased protein intake (IPET+P) receiving 27.5 g protein/day
Study: 33243811
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with protein supplementation (UC+P) receiving 27.5 g protein/day
Study: 35780048
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) plus radical local therapy (RLT)
Study: 37351372
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) therapy
Study: 35190177
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg intravenously on days 1, 15, and 29; n = 23)
Study: 35190177
Drug: Nivolumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab with ipilimumab (1 mg/kg intravenously on day 1; n = 21)
Study: 34702332
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (single‐dose muscle relaxant administration at induction)
Study: 32886321
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants (DOACs) - Dabigatran (66%), Apixaban (21%), Rivaroxaban (13%); 58% prescribed reduced dose.
Study: 35562830
Drug: Meridian theory-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meridian theory-based extracorporeal shock wave therapy (ESWT)
Study: 35562830
Drug: Conventional extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional extracorporeal shock wave therapy (ESWT)
Study: 33490019
Drug: Per capita
Normalized name: Lespedeza capitata flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per capita monthly income
Study: 33676295
Drug: FOLFOXIRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOXIRI treatment
Study: 35588050
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously every 4 weeks for 6 cycles
Study: 35588050
Drug: Nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 125 mg/m2 weekly for 12 weeks
Study: 35588050
Drug: Nab-paclitaxel days
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel days 1 and 8 every 3 weeks for 4 cycles (8 doses)
Study: 35588050
Drug: Nab-paclitaxel weekly
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel weekly
Study: 35864302
Drug: Cinnarizine 20
Normalized name: cinnarizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 20 mg and Dimenhydrinate 40 mg
Study: 35960902
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg twice a day orally
Study: 32316331
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy group
Study: 36203323
Drug: Active cTBS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active cTBS treatment
Study: 36203323
Drug: Sham cTBS
Normalized name: Syn023 component ctb-011
DrugBank: Zamerovimab (DB17766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham cTBS treatment
Study: 32096437
Drug: Lomb-Scargle (L-S)
Normalized name: L-S-Adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomb-Scargle (L-S) periodogram
Study: 32162607
Drug: Mg citrate
Normalized name: K-Mg Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg citrate (MgC)
Study: 32162607
Drug: Mg oxide
Normalized name: citric acid/Mg oxide/Na picosulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg oxide (MgO)
Study: 33907188
Drug: Duloxetine (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (serotonin and noradrenaline reuptake inhibitor)
Study: 34910143
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) Implant
Study: 33928827
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy and combined oral contraceptives
Study: 32384500
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of intravenous dexamethasone and 1 dose of normal saline (Group A)
Study: 32384500
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of intravenous dexamethasone (Group B)
Study: 36562419
Drug: Low-dose fenfluramine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fenfluramine
Study: 32976660
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prednisolone
Study: 35196580
Drug: Heating therapy
Normalized name: MENTHOL 2.8 g in 56 g TOPICAL CREAM [elevate HEATING THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heating therapy
Study: 35196580
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heating therapy)
Study: 35649607
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual Optimised (TAU-O)
Study: 33448754
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - only had their symptoms monitored through phone calls, maintaining usual care treatment
Study: 33706319
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy (BT)
Study: 35287480
Drug: Yangxin Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxin Recipe (YXR) + conventional western medicine
Study: 35691324
Drug: ChAdOx1 nCoV‐19
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV‐19 (AZD1222) vaccine, 5 × 10^10 viral particles, two doses
Study: 35691324
Drug: Capsular group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsular group B meningococcal vaccine (control)
Study: 33934714
Drug: Levetiracetam (1000–3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1000–3000 mg)
Study: 33934714
Drug: Fosphenytoin (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosphenytoin (22.5 mg/kg)
Study: 34052232
Drug: IV sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sildenafil (loading: 0.1 mg/kg over 30 minutes; maintenance: 0.03 mg/kg/h)
Study: 32240542
Drug: Mobile text
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile text messaging (3 to 5 messages daily for one month)
Study: 36197388
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use prevention program #TamoJunto2.0
Study: 32660769
Drug: MSB11455 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB11455 (6 mg/0.6 mL)
Study: 32333641
Drug: Neulasta® (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neulasta® (6 mg/0.6 mL)
Study: 32164428
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (0.5 mcg/kg/min)
Study: 32500486
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily plus Metformin 1000 mg once daily for 12 weeks
Study: 32500486
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily plus placebo for 12 weeks
Study: 33770125
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of using oral contraceptive pills
Study: 32198342
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus over 30 min, followed by 1 mg/kg/h continuous infusion for 6 h)
Study: 39025264
Drug: vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle cream
Study: 33962592
Drug: CPI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI treatment combined with SBRT (Arm A)
Study: 33962592
Drug: CPI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI monotherapy (Arm B)
Study: 32997046
Drug: Post-treatment evaluation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment evaluation
Study: 32997046
Drug: POC‐CCA test
Approvals — FDA: no, EMA: no, PMDA: no
Description: POC‐CCA test post-treatment
Study: 33341955
Drug: Tegoprazan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan (50 mg and 100 mg) coadministered with amoxicillin/clarithromycin (1000/500 mg) for 7 days
Study: 33341955
Drug: Pantoprazole-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole-based triple therapy
Study: 38847412
Drug: Rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.3 mg/kg
Study: 33413594
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg once daily for 36 months
Study: 32955410
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (CC)
Study: 32955410
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy plus adjuvant chemotherapy (CC + AC)
Study: 32955410
Drug: Overall comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall comparison of IC, CC, and CC + AC
Study: 35468847
Drug: Salbutamol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (single intravenous injection)
Study: 32521736
Drug: Escitalopram (SSRI),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (SSRI), 6-week treatment
Study: 32521736
Drug: Placebo, 6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 6-week treatment
Study: 34689669
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control video
Study: 33653685
Drug: High oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oxygen protocol (6-8 L/min by face mask)
Study: 34734297
Drug: Coated implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated implant (TiNiN)
Study: 34734297
Drug: Standard implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard implant (CoCr)
Study: 32235930
Drug: Underfeeding and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underfeeding and Oral vancomycin
Study: 35995733
Drug: ACB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACB with 20 mL of 0.5% ropivacaine
Study: 32581409
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) therapy
Study: 32229139
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g dark chocolate containing 410 mg of flavanols per day
Study: 32229139
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g dark chocolate containing 86 mg of flavanols per day
Study: 35452108
Drug: 8-week weight
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week weight loss and lifestyle intervention (nutritional behavior change, aerobic exercise, sleep hygiene, alcohol and tobacco cessation) combined with usual care (CPAP therapy)
Study: 35452108
Drug: usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual care (CPAP therapy)
Study: 35101094
Drug: BioBlock nasal
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioBlock nasal spray (intervention)
Study: 35101094
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (control)
Study: 35273566
Drug: LT3 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT3 monotherapy for 12 weeks
Study: 35273566
Drug: LT4 monotherapy
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 monotherapy for 12 weeks
Study: 33431075
Drug: Endovascular Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Therapy (EVT)
Study: 33250038
Drug: Endovascular Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Therapy (EVT) with CT selection
Study: 33250038
Drug: Endovascular Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Therapy (EVT) with MRI selection
Study: 35164833
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice reinforced by weekly supportive phone/email support for 4 weeks.
Study: 35164833
Drug: Potassium supplement
Normalized name: Potassium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplement prescribed if no increase in potassium intake after 4 weeks.
Study: 35164833
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice and potassium supplement.
Study: 35164833
Drug: Concurrent measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent measurements of sodium intake, blood pressure, participant satisfaction, and safety measures.
Study: 33774529
Drug: Steroid-treated transfers
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-treated transfers
Study: 32501812
Drug: Prenatal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal treatment (specifics not provided)
Study: 32264698
Drug: Prothrombin complex
Normalized name: prothrombin complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prothrombin complex concentrates (PCCs) administered to patients with factor Xa inhibitor-related ICH
Study: 32340638
Drug: IbET (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: IbET (internet-based extinction therapy)
Study: 36120805
Drug: Cold Atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Atmospheric Plasma (CAP) technology, treated biweekly for five sessions with a follow-up 30 days after final treatment
Study: 34008703
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with low-dose morphine (15 mcg/kg)
Study: 34008703
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with clonidine (1 mcg/kg)
Study: 32493459
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of expanded umbilical cord blood cells at a dose of 5 million cells/kg (maximum dose - 500 million cells)
Study: 34836205
Drug: Xylitol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (8 g three times a day for five to seven weeks)
Study: 34836205
Drug: Erythritol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol (12 g three times a day for five to seven weeks)
Study: 36099069
Drug: Saxagliptin +
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin + Metformin (Saxa+Met)
Study: 32910141
Drug: Reslizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab (1.0 mg/kg IV)
Study: 32910141
Drug: DEC treatment
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC treatment
Study: 34922447
Drug: Pragmatic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic combination of behavioural science and evidence-based techniques in study invitation letter
Study: 35573797
Drug: Risk score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk score based on clinical factors and lymphocyte subtyping including CD8+ T-cell count ≤143 cells/mm3, high-dose corticosteroids (≥50 mg prednisolone equivalent), carbapenem/tigecycline, APACHE II score ≥15, (1,3)-β-D-glucan positivity, emergency gastrointestinal/hepatobiliary surgery.
Study: 32799994
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy interventions
Study: 34137783
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy
Study: 35487873
Drug: HLA-G +3142GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G +3142GG genotype in alloimmunized patients with antibodies against Rh and Kell antigens
Study: 35487873
Drug: HLA-G +14
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HLA-G +14 bp Ins/Del and +3142 C>G variations
Study: 36680919
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg DHA
Study: 32698912
Drug: Calanus finmarchicus
Normalized name: calamus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calanus finmarchicus oil (CO) 2g daily providing 124 mg stearidonic acid, 109 mg EPA, and 87 mg DHA
Study: 32470710
Drug: pegylated interferon-alfa2b
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon-alfa2b (PEG-IFNα-2b) at 3 μg/kg/week subcutaneously for 2 years
Study: 34765950
Drug: GM1 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM1 (60 mg daily for 3 weeks or 40 mg daily for 2 weeks)
Study: 33543381
Drug: Subgingival debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival debridement (SD) with light-activated disinfection (LAD) plus probiotic treatment
Study: 32921680
Drug: Dapagliflozin 5
Normalized name: dapagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5 mg/day add-on
Study: 32921680
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy add-on
Study: 36153496
Drug: Atezolizumab maintenance
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab maintenance therapy with thoracic radiotherapy (TRT)
Study: 36153496
Drug: Atezolizumab maintenance
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab maintenance therapy without thoracic radiotherapy (TRT)
Study: 37037952
Drug: Chemotherapy (KEYNOTE-061)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (KEYNOTE-061)
Study: 37037952
Drug: Chemotherapy (KEYNOTE-062)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (KEYNOTE-062)
Study: 34185259
Drug: Denosumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (120 mg) subcutaneously every 3–4 weeks for about 6 months and then every 3 months for a total treatment duration of 5 years
Study: 34185259
Drug: Denosumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (120 mg) subcutaneously
Study: 33032163
Drug: Floatation‐restricted environmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floatation‐restricted environmental stimulation therapy (floatation‐REST)
Study: 34159460
Drug: Senna laxative
Normalized name: Senna Laxative
DrugBank: Sennosides (DB11365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Senna laxative for 3 days followed by low volume PEG on examination day
Study: 34159460
Drug: Senna laxative
Normalized name: Senna Laxative
DrugBank: Sennosides (DB11365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Senna laxative
Study: 34521554
Drug: Lurbinectedin 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin 3.2 mg/m2 1-h i.v. infusion q3wk
Study: 34521554
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 1-h i.v. infusion q4wk or topotecan 1.50 mg/m2 30-min i.v. infusion Days 1-5 q3wk
Study: 33200180
Drug: Diet-related interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet-related interventions (diet and/or behavioral manipulation, provision of foods or entire meals, or delivery of dietary components in individual food items or supplements)
Study: 33878954
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy plus pembrolizumab
Study: 33878954
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy followed by pembrolizumab
Study: 33878954
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care adjuvant platinum-based chemotherapy
Study: 35238401
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (target‐controlled total intravenous anaesthesia with propofol and remifentanil)